Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
EGFR and HER2 inhibitors act on two closely related receptor tyrosine kinases of the ErbB family. The epidermal growth factor receptor (EGFR, ErbB1) and human epidermal growth factor receptor 2 (HER2, ErbB2) form dimers with each other and with ErbB3 and ErbB4. Receptor activation engages the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways that control cell growth. Activating EGFR mutations in non-small-cell lung cancer have made the receptor a central model in kinase inhibitor research. Gefitinib and erlotinib are reversible EGFR inhibitors, and lapatinib inhibits both EGFR and HER2. Osimertinib binds covalently to EGFR carrying the T790M resistance mutation, and neratinib irreversibly inhibits HER2 and EGFR.
Epidermal Growth Factor Receptor Peptide (985-996) exists on the cell surface and is activated by the binding of its specific ligands, including epidermal growth factor and transforming growth factor.
EGFR ligand-14-PEG3-Boc is a compound designed for targeted conjugation involving the epidermal growth factor receptor (EGFR). This reagent incorporates an EGFR ligand and a polyethylene glycol (PEG) linker, facilitating the synthesis of SJF-1521. It is particularly useful in research applications focusing on drug delivery systems and targeted therapies that exploit the EGFR signaling pathway.
Out of stock
All 3 sizes
EGFR ligand-11 is a specific ligand for the epidermal growth factor receptor (EGFR). This compound plays a crucial role in synthesizing PROTAC MS154, facilitating targeted protein degradation of EGFR-related pathways. It is valuable for research applications focused on understanding EGFR signaling and developing therapeutic strategies for EGFR-driven cancers.
Out of stock
All 3 sizes
EGFR ligand-14 is a specific ligand for the Epidermal Growth Factor Receptor (EGFR), a key target in cancer research. This compound facilitates studies on EGFR signaling pathways and can be utilized in the synthesis of SJF-1521. Its role in modulating EGFR activity makes it valuable for the investigation of targeted therapies in oncogenic processes.
Out of stock
All 3 sizes
EGFR ligand-9 is a specific ligand for the epidermal growth factor receptor (EGFR). It is designed for use in the synthesis of PROTAC EGFR degrader 9, facilitating the targeted degradation of EGFR in research applications. This compound is valuable for studying EGFR signaling pathways and developing novel therapeutic strategies in cancer research.
(+)−Theta-cypermethrin is a stereoisomer of cypermethrin that functions as a selective binder to AKT1, SRC, STAT3, and epidermal growth factor receptor (EGFR). This compound is known to penetrate the blood-brain barrier, leading to alterations in the amplitude of delayed rectifier potassium channel currents and significant shifts in the activation and inactivation curves at elevated concentrations. Additionally, (+)-Theta-cypermethrin induces abnormal electrical activity in rat hippocampal neurons and is associated with chronic respiratory system damage and neurotoxicity. It serves as a valuable tool for research into signal transduction pathways and neuropharmacology.
Out of stock
All 3 sizes![Cyclo[K(N3)larllt]](https://www.adooq.com/media/catalog/product/cache/16359f9c8ddfa823fcb5503b1e11b7ae/b/2/b21825-cyclo-k-n3-larllt.gif)
Cyclo[K(N3)larllt] is a cyclic peptide that specifically targets the epidermal growth factor receptor (EGFR) with a Kd value of 5.09 μM and demonstrates selectivity for related proteins HER2 and HER3. This compound exhibits no cytotoxicity and does not inhibit the growth of EGFR-overexpressing cancer cells. Cyclo[K(N3)larllt] is ideal for use as a ligand in EGFR-targeted fluorescent conjugates, facilitating the detection of tumors with elevated EGFR levels. Its applications extend to research focused on colorectal cancer and related pathologies.
Out of stock
All 3 sizes